This article gives an overview of neuroprotective drugs that were recently tested in clinical trials in cardiac surgery. Also, recommendations are given for successful translational research and considerations for management during cardiac surgery.
McKhann GM, Goldsborough MA, Borowicz LM Jr, et al. Predictors of stroke risk in coronary artery bypass patients . Ann Thorac Surg. 1997;63:516-521.
2.
van Dijk D., Moons KG, Keizer AM, et al; Octopus Study Group.Association between early and three month cognitive outcome after off-pump and on-pump coronary bypass surgery. Heart.2004;90:431-434.
3.
van Dijk D., Spoor M., Hijman R., et al; Octopus Study Group.Cognitive and cardiac outcomes 5 years after off-pump vs on-pump coronary artery bypass graft surgery. JAMA. 2007;297:701-708.
4.
Dacey LJ, Likosky DS, Leavitt BJ, et al. Perioperative stroke and long-term survival after coronary bypass graft surgery. Ann Thorac Surg. 2005;79:532-536.
5.
McKhann GM, Grega MA, Borowicz LM Jr, Baumgartner WA, Selnes OAStroke and encephalopathy after cardiac surgery: an update. Stroke. 2006;37:562-571.
6.
Boeken U., Litmathe J., Feindt P., Gams E.Neurological complications after cardiac surgery: risk factors and correlation to the surgical procedure. Thorac Cardiovasc Surg. 2005;53:33-36.
7.
Savitz SI, Fisher M.Prophylactic neuroprotection. Curr Drug Targets. 2007;8:846-849.
8.
Hogue CW Jr , Palin CA , Arrowsmith JECardiopulmonary bypass management and neurologic outcomes: an evidence-based appraisal of current practices. Anesth Analg. 2006;103:21-37.
9.
Erdos G., Tzanova I., Schirmer U., Ender J.Neuromonitoring and neuroprotection in cardiac anaesthesia. Nationwide survey conducted by the Cardiac Anaesthesia Working Group of the German Society of Anaesthesiology and Intensive Care Medicine [in German]. Anaesthesist. 2009;58:247-258.
10.
Goldstein A. Jr , Wells BA , Keats ASIncreased tolerance to cerebral anoxia by pentobarbital. Arch Int Pharmacodyn Ther. 1966;161:138-143.
11.
Slogoff S., Girgis KZ, Keats ASEtiologic factors in neuropsychiatric complications associated with cardiopulmonary bypass. Anesth Analg. 1982;61:903-911.
12.
Nussmeier NA, Arlund C., Slogoff S.Neuropsychiatric complications after cardiopulmonary bypass: cerebral protection by a barbiturate. Anesthesiology. 1986;64:165-170.
13.
Zaidan JR, Klochany A., Martin WM, Ziegler JS, Harless DM, Andrews RBEffect of thiopental on neurologic outcome following coronary artery bypass grafting. Anesthesiology. 1991;74:406-411.
14.
Donegan JH, Traystman RJ, Koehler RC, Jones MD Jr, Rogers MCCerebrovascular hypoxic and autoregulatory responses during reduced brain metabolism. Am J Physiol.1985;249(2 Pt 2):H421-H429.
15.
Elsersy H., Sheng H., Lynch JR, Moldovan M., Pearlstein RD, Warner DSEffects of isoflurane versus fentanyl-nitrous oxide anesthesia on long-term outcome from severe forebrain ischemia in the rat. Anesthesiology . 2004;100:1160-1166.
16.
Sakai H., Sheng H., Yates RB, Ishida K., Pearlstein RD, Warner DSIsoflurane provides long-term protection against focal cerebral ischemia in the rat. Anesthesiology. 2007;106: 92-99.
17.
Pape M., Engelhard K., Eberspacher E., et al. The long-term effect of sevoflurane on neuronal cell damage and expression of apoptotic factors after cerebral ischemia and reperfusion in rats. Anesth Analg. 2006;103:173-179.
18.
Nellgard B. , Mackensen GB, Pineda J., Wellons JC III, Pearlstein RD, Warner DSAnesthetic effects on cerebral metabolic rate predict histologic outcome from near-complete forebrain ischemia in the rat. Anesthesiology. 2000;93:431-436.
19.
Canas PT, Velly LJ, Labrande CN, et al. Sevoflurane protects rat mixed cerebrocortical neuronal-glial cell cultures against transient oxygen-glucose deprivation: involvement of glutamate uptake and reactive oxygen species. Anesthesiology . 2006;105:990-998.
20.
Elsersy H., Mixco J., Sheng H., Pearlstein RD, Warner DSSelective gamma-aminobutyric acid type A receptor antagonism reverses isoflurane ischemic neuroprotection. Anesthesiology. 2006;105:81-90.
21.
Harada H., Kelly PJ, Cole DJ, Drummond JC, Patel PMIsoflurane reduces N-methyl-D-aspartate toxicity in vivo in the rat cerebral cortex. Anesth Analg. 1999;89:1442-1447.
22.
Davis DP, Patel PMIschemic preconditioning in the brain. Curr Opin Anaesthesiol . 2003;16:447-452.
23.
Cold GE, Eskesen V., Eriksen H., Blatt LBChanges in CMRO2, EEG and concentration of etomidate in serum and brain tissue during craniotomy with continuous etomidate supplemented with N2O and fentanyl . Acta Anaesthesiol Scand. 1986;30:159-163.
24.
Kaisti KK, Langsjo JW, Aalto S., et al. Effects of sevoflurane, propofol, and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption, and blood volume in humans . Anesthesiology. 2003;99:603-613.
25.
Rodriguez-Lopez JM, Sanchez-Conde P., Lozano FS, et al. Laboratory investigation: effects of propofol on the systemic inflammatory response during aortic surgery. Can J Anaesth.2006;53:701-710.
26.
Ito H., Watanabe Y., Isshiki A., Uchino H.Neuroprotective properties of propofol and midazolam, but not pentobarbital, on neuronal damage induced by forebrain ischemia, based on the GABAA receptors . Acta Anaesthesiol Scand. 1999;43: 153-162.
27.
Roach GW, Newman MF, Murkin JM, et al. Ineffective-ness of burst suppression therapy in mitigating perioperative cerebrovascular dysfunction. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Anesthesiology. 1999;90:1255-1264.
28.
Kadoi Y., Saito S., Kunimoto F., Goto F., Fujita N.Comparative effects of propofol versus fentanyl on cerebral oxygenation state during normothermic cardiopulmonary bypass and postoperative cognitive dysfunction . Ann Thorac Surg. 2003;75:840-846.
29.
Mitchell SJLidocaine in the treatment of decompression illness: a review of the literature. Undersea Hyperb Med. 2001;28:165-174.
30.
Evans DE, Kobrine AI, LeGrys DC, Bradley MEProtective effect of lidocaine in acute cerebral ischemia induced by air embolism . J Neurosurg. 1984;60:257-263.
31.
Mitchell SJ , Pellett O., Gorman DFCerebral protection by lidocaine during cardiac operations. Ann Thorac Surg. 1999;67:1117-1124.
32.
Wang D., Wu X., Li J., Xiao F., Liu X., Meng M.The effect of lidocaine on early postoperative cognitive dysfunction after coronary artery bypass surgery. Anesth Analg. 2002;95: 1134-1141.
33.
Mathew JP, Mackensen GB, Phillips-Bute B., et al. Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery. Stroke. 2009;40:880-887.
34.
Arrowsmith JE, Harrison MJ, Newman SP, Stygall J., Timberlake N., Pugsley WBNeuroprotection of the brain during cardiopulmonary bypass: a randomized trial of remacemide during coronary artery bypass in 171 patients. Stroke. 1998;29:2357-2362.
35.
Dorhout MS, Rinkel G., Feigin V., et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage . Cochrane Database Syst Rev2007;(3):CD000277.
36.
Forsman M., Olsnes BT, Semb G., Steen PAEffects of nimodipine on cerebral blood flow and neuropsychological outcome after cardiac surgery. Br J Anaesth. 1990;65:514-520.
37.
Legault C., Furberg CD, Wagenknecht LE, et al. Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial. Stroke. 1996 ;27:593-598.
38.
Vergouwen MD, Vermeulen M., de Haan RJ, Levi M., Roos YBDihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review. J Cereb Blood Flow Metab. 2007;27:1293-1308.
39.
Nagels W., Demeyere R., Van HJ, Vandenbussche E., Gijbels K., Vandermeersch E.Evaluation of the neuroprotective effects of S(+)-ketamine during open-heart surgery. Anesth Analg. 2004;98:1595-1603.
40.
Hudetz JA, Iqbal Z., Gandhi SD, et al. Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery. Acta Anaesthesiol Scand. 2009;53:864-872.
41.
Dickinson R. , Peterson BK, Banks P., et al. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology. Anesthesiology . 2007;107:756-767.
42.
Ma D., Yang H., Lynch J., Franks NP, Maze M., Grocott HPXenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. Anesthesiology. 2003 ;98:690-698.
43.
Jungwirth B. , Gordan ML, Blobner M., Schmehl W., Kochs EF, Mackensen GBXenon impairs neurocognitive and histologic outcome after cardiopulmonary bypass combined with cerebral air embolism in rats. Anesthesiology. 2006;104:770-776.
44.
Lockwood GG , Franks NP, Downie NA, Taylor KM, Maze M.Feasibility and safety of delivering xenon to patients undergoing coronary artery bypass graft surgery while on cardiopulmonary bypass: phase I study. Anesthesiology. 2006 ;104:458-465.
45.
van den Bergh WM, Dijkhuizen RM, Rinkel GJPotentials of magnesium treatment in subarachnoid haemorrhage. Magnes Res. 2004;17:301-313.
46.
van den Bergh WM, Algra A., van Kooten F., et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2005;36:1011-1015.
47.
van den Bergh WMMagnesium in subarachnoid haemorrhage: proven beneficial? Magnes Res. 2009;22:121-126.
48.
Dorhout Mees SMMagnesium in aneurysmal subarachnoid hemorrhage (MASH II) phase III clinical trial MASH-II study group. Int J Stroke. 2008;3:63-65.
49.
Shepherd J. , Jones J., Frampton GK, Tanajewski L., Turner D., Price A.Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. Health Technol Assess. 2008;12(28):iii-95.
50.
Bhudia SK, Cosgrove DM, Naugle RI, et al. Magnesium as a neuroprotectant in cardiac surgery: a randomized clinical trial. J Thorac Cardiovasc Surg. 2006;131:853-861.
51.
Mathew JP, Lombard WF, Mackensen GB, White WD, Blumenthal JA, Newman MFIntraoperative magnesium administration does not decrease neurocognitive dysfunction after cardiac surgery. Anesth Analg.2009;108:SCA10.
52.
Huber JD, Egleton RD, Davis TPMolecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 2001;24:719-725.
53.
Laursen H., Bodker A., Andersen K., Waaben J., Husum B.Brain oedema and blood-brain barrier permeability in pulsatile and nonpulsatile cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg. 1986;20:161-166.
Qizilbash N. , Lewington SL, Lopez-Arrieta JMCorticosteroids for acute ischaemic stroke . Cochrane Database Syst Rev2002;(2):CD000064.
56.
Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med1990;322:1405-1411.
57.
Sapolsky RMStress, glucocorticoids, and damage to the nervous system: the current state of confusion. Stress. 1996;1:1-19.
58.
Edwards P., Arango M., Balica L., et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet. 2005;365:1957-1959.
59.
Jastremski M., Sutton-Tyrrell K., Vaagenes P., Abramson N., Heiselman D., Safar P.Glucocorticoid treatment does not improve neurological recovery following cardiac arrest. Brain Resuscitation Clinical Trial I Study Group. JAMA. 1989;262:3427-3430.
60.
Lanier WLThe prevention and treatment of cerebral ischemia. Can J Anaesth . 1999;46(5 Pt 2):R46-R56.
61.
Shum-Tim D. , Tchervenkov CI, Jamal AM, et al. Systemic steroid pretreatment improves cerebral protection after circulatory arrest. Ann Thorac Surg.2001;72:1465-1471.
62.
Levy JH, Pifarre R., Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 1995;92:2236-2244.
63.
Smith PK, Datta SK, Muhlbaier LH, Samsa G., Nadel A., Lipscomb J.Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials. Ann Thorac Surg. 2004 ;77:635-642.
64.
Smith PK, Muhlbaier LHAprotinin: safe and effective only with the full-dose regimen. Ann Thorac Surg. 1996;62: 1575-1577.
65.
Frumento RJ , O’Malley CM, Bennett-Guerrero E.Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens . Ann Thorac Surg. 2003;75:479-483.
66.
Harmon DC, Ghori KG, Eustace NP, O’Callaghan SJ, O’Donnell AP, Shorten GDAprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. Can J Anaesth. 2004;51:1002-1009.
67.
Lord RA, Roath OS, Thompson JF, Chant AD, Francis JLEffect of aprotinin on neutrophil function after major vascular surgery. Br J Surg. 1992;79:517-521.
68.
Hill GE, Alonso A., Spurzem JR, Stammers AH, Robbins RAAprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg. 1995;110:1658-1662.
69.
Grocott HP, Sheng H., Miura Y., et al. The effects of aprotinin on outcome from cerebral ischemia in the rat. Anesth Analg. 1999;88:1-7.
70.
Mangano DT, Tudor IC, Dietzel C.The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-365.
71.
Mangano DT, Miao Y., Vuylsteke A., et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007;297:471-479.
72.
Levy JH, Tanaka KAInflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003;75:S715-S720.
73.
Testa L., Van Gaal WJ, Bhindi R., et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg . 2008;136:884-893.
74.
Mathew JP, Shernan SK, White WD, et al. Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. Stroke. 2004;35:2335-2339.
75.
Fish KJ, Helms KN, Sarnquist FH, et al. A prospective, randomized study of the effects of prostacyclin on neuropsychologic dysfunction after coronary artery operation. J Thorac Cardiovasc Surg. 1987;93:609-615.
76.
Fish KJ, Sarnquist FH, van SC, et al. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. J Thorac Cardiovasc Surg.1986;91:436-442.
77.
Taggart DP, Browne SM, Wade DT, Halligan PWNeuroprotection during cardiac surgery: a randomised trial of a platelet activating factor antagonist. Heart. 2003;89:897-900.
78.
Sena E., Wheble P., Sandercock P., Macleod M.Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke. 2007;38:388-394.
79.
Bath PM, Gray LJ, Bath AJ, Buchan A., Miyata T., Green AREffects of NXY-059 in experimental stroke: an individual animal meta-analysis . Br J Pharmacol. 2009;157:1157-1171.
80.
Bath PM, Iddenden R., Bath FJ, Orgogozo JMTirilazad for acute ischaemic stroke. Cochrane Database Syst Rev.2001;(4):CD002087.
81.
Jang YG, Ilodigwe D., Macdonald RLMetaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2009;10:141-147.
82.
Shuaib A., Lees KR, Lyden P., et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571.
83.
Mathew JP, Mackensen GB, Phillips-Bute B., et al. Effects of extreme hemodilution during cardiac surgery on cognitive function in the elderly. Anesthesiology.2007 ;107:577-584.
84.
Hogue CW Jr , Freedland K., Hershey T., et al. Neurocognitive outcomes are not improved by 17beta-estradiol in postmenopausal women undergoing cardiac surgery. Stroke. 2007;38:2048-2054.
85.
Stanley TO, Mackensen GB, Grocott HP, et al. The impact of postoperative atrial fibrillation on neurocognitive outcome after coronary artery bypass graft surgery. Anesth Analg. 2002;94:290-295.
86.
Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004;291:1720-1729.
87.
Amory DW, Grigore A., Amory JK, et al. Neuroprotection is associated with beta-adrenergic receptor antagonists during cardiac surgery: evidence from 2,575 patients. J Cardiothorac Vasc Anesth. 2002;16:270-277.
88.
Savitz SI, Erhardt JA, Anthony JV, et al. The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab. 2000;20:1197-1204.
89.
Murry CE, Jennings RB, Reimer KAPreconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium . Circulation. 1986;74:1124-1136.
90.
Kitagawa K. , Matsumoto M., Tagaya M., et al. ‘Ischemic tolerance" phenomenon found in the brain. Brain Res. 1990;528: 21-24.
91.
Davis DP, Patel PMIschemic preconditioning in the brain. Curr Opin Anaesthesiol . 2003;16:447-452.
92.
Shake JG, Peck EA, Marban E., et al. Pharmacologically induced preconditioning with diazoxide: a novel approach to brain protection. Ann Thorac Surg. 2001;72:1849-1854.
93.
Meco M., Cirri S., Gallazzi C., Magnani G., Cosseta D.Desflurane preconditioning in coronary artery bypass graft surgery: a double-blinded, randomised and placebo-controlled study. Eur J Cardiothorac Surg. 2007;32:319-325.
94.
Payne RS, Akca O., Roewer N., Schurr A., Kehl F.Sevoflurane-induced preconditioning protects against cerebral ischemic neuronal damage in rats. Brain Res. 2005;1034: 147-152.
95.
Fisher M.Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke. 2003;34:1539-1546.
96.
O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW1,026 experimental treatments in acute stroke . Ann Neurol.2006;59:467-477.
97.
Philip M., Benatar M., Fisher M., Savitz SIMethodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke. 2009;40:577-581.
98.
Fisher M., Feuerstein G., Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244-2250.
99.
Sanders RD, Maze M.Xenon: from stranger to guardian. Curr Opin Anaesthesiol. 2005;18:405-411.
